{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:53:59Z","timestamp":1768683239685,"version":"3.49.0"},"reference-count":79,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2020"],"award-info":[{"award-number":["Ricerca Corrente 2020"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Muscular dystrophies are a heterogeneous group of inherited diseases characterized by the progressive degeneration and weakness of skeletal muscles, leading to disability and, often, premature death. To date, no effective therapies are available to halt or reverse the pathogenic process, and meaningful treatments are urgently needed. From this perspective, it is particularly important to establish reliable in vitro models of human muscle that allow the recapitulation of disease features as well as the screening of genetic and pharmacological therapies. We herein review and discuss advances in the development of in vitro muscle models obtained from human induced pluripotent stem cells, which appear to be capable of reproducing the lack of myofiber proteins as well as other specific pathological hallmarks, such as inflammation, fibrosis, and reduced muscle regenerative potential. In addition, these platforms have been used to assess genetic correction strategies such as gene silencing, gene transfer and genome editing with clustered regularly interspaced short palindromic repeats (CRISPR)\/CRISPR-associated protein 9 (Cas9), as well as to evaluate novel small molecules aimed at ameliorating muscle degeneration. Furthermore, we discuss the challenges related to in vitro drug testing and provide a critical view of potential therapeutic developments to foster the future clinical translation of preclinical muscular dystrophy studies.<\/jats:p>","DOI":"10.3390\/ijms22179630","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T21:47:38Z","timestamp":1630964858000},"page":"9630","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Perspectives on hiPSC-Derived Muscle Cells as Drug Discovery Models for Muscular Dystrophies"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0797-8282","authenticated-orcid":false,"given":"Elena","family":"Abati","sequence":"first","affiliation":[{"name":"Neuroscience Section, Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), University of Milan, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Sclarandi","sequence":"additional","affiliation":[{"name":"Neuroscience Section, Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), University of Milan, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo Pietro","family":"Comi","sequence":"additional","affiliation":[{"name":"Neuroscience Section, Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), University of Milan, 20122 Milan, Italy"},{"name":"Fondazione IRCCS Ca\u2019 Granda\u2014Ospedale Maggiore Policlinico, Neurology Unit, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Parente","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda\u2014Ospedale Maggiore Policlinico, Neurology Unit, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[{"name":"Neuroscience Section, Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), University of Milan, 20122 Milan, Italy"},{"name":"Fondazione IRCCS Ca\u2019 Granda\u2014Ospedale Maggiore Policlinico, Neurology Unit, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2044-5040-1-21","article-title":"Aberrant repair and fibrosis development in skeletal muscle","volume":"1","author":"Mann","year":"2011","journal-title":"Skelet. Muscle"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/CPJ.0000000000000531","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 1","volume":"8","author":"Ashizawa","year":"2018","journal-title":"Neurol. Clin. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/CPJ.0000000000000645","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 2","volume":"9","author":"Schoser","year":"2019","journal-title":"Neurol. Clin. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ncl.2020.03.009","article-title":"Limb girdle muscular dystrophies","volume":"38","author":"Bockhorst","year":"2020","journal-title":"Neurol. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cccn.2005.05.020","article-title":"Molecular etiopathogenesis of limb girdle muscular and congenital muscular dystrophies: Boundaries and contiguities","volume":"361","author":"Guglieri","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.25192","article-title":"The italian limb girdle muscular dystrophy registry: Relative frequency, clinical features, and differential diagnosis","volume":"55","author":"Magri","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/humu.21114","article-title":"Mutational spectrum of DMD mutations in dystrophinopathy patients: Application of modern diagnostic techniques to a large cohort","volume":"30","author":"Flanigan","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: One gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s00415-011-5979-z","article-title":"Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up","volume":"258","author":"Magri","year":"2011","journal-title":"J. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"134833","DOI":"10.1016\/j.neulet.2020.134833","article-title":"The role of the dystrophin glycoprotein complex on the neuromuscular system","volume":"722","author":"Belhasan","year":"2020","journal-title":"Neurosci. Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","article-title":"Ataluren: First global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI136873","article-title":"Correction of muscular dystrophies by CRISPR gene editing","volume":"130","author":"Chemello","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11910-020-01034-6","article-title":"Update on muscular dystrophies with focus on novel treatments and biomarkers","volume":"20","author":"Datta","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1007\/s00018-013-1396-z","article-title":"Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy","volume":"70","author":"Govoni","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2352-4642(18)30140-8","article-title":"Genetic therapies for inherited neuromuscular disorders","volume":"2","author":"Scoto","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000016776","article-title":"Differentiation of myoblasts in serum-free media: Effects of modified media are cell line-specific","volume":"167","author":"Lawson","year":"2000","journal-title":"Cells Tissues Organs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1039\/c1ib00058f","article-title":"Patterning the differentiation of C2C12 skeletal myoblasts","volume":"3","author":"Bajaj","year":"2011","journal-title":"Integr. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"C339","DOI":"10.1152\/ajpcell.00343.2018","article-title":"Robust intrinsic differences in mitochondrial respiration and H2O2 emission between L6 and C2C12 cells","volume":"317","author":"Robinson","year":"2019","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"44312","DOI":"10.1038\/srep44312","article-title":"Emerin plays a crucial role in nuclear invagination and in the nuclear calcium transient","volume":"7","author":"Shimojima","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15927","DOI":"10.1074\/jbc.M213102200","article-title":"Conditional expression of SV40 T-antigen in mouse cardiomyocytes facilitates an inducible switch from proliferation to differentiation","volume":"278","author":"Rybkin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41467-020-20760-6","article-title":"Perspectives on skeletal muscle stem cells","volume":"12","author":"Relaix","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.yexcr.2003.12.015","article-title":"Skeletal muscle differentiation potential of human adult bone marrow cells","volume":"295","author":"Bossolasco","year":"2004","journal-title":"Exp. Cell Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2174\/156652312800840559","article-title":"The role of stem cells in muscular dystrophies","volume":"12","author":"Meregalli","year":"2012","journal-title":"Curr. Gene Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fusco-Allison, G., Li, D.K., Hunter, B., Jackson, D., Bannon, P.G., Lal, S., and O\u2019Sullivan, J.F. (2021). Optimizing the discovery and assessment of therapeutic targets in heart failure with preserved ejection fraction. ESC Heart Fail., ehf2.13504.","DOI":"10.1002\/ehf2.13504"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.2006.0081","article-title":"Embryonic stem cells","volume":"16","author":"Biswas","year":"2007","journal-title":"Stem Cells Dev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1582-4934.2011.01498.x","article-title":"Generation of skeletal muscle cells from embryonic and induced pluripotent stem cells as an in vitro model and for therapy of muscular dystrophies","volume":"16","author":"Salani","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1756286419833478","DOI":"10.1177\/1756286419833478","article-title":"Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophies","volume":"12","author":"Piga","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lfs.2015.12.023","article-title":"Human cardiomyocyte generation from pluripotent stem cells: A state-of-art","volume":"145","author":"Talkhabi","year":"2016","journal-title":"Life Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1242\/dmm.030320","article-title":"Human pluripotent stem cell models of cardiac disease: From mechanisms to therapies","volume":"10","author":"Tabel","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5966\/sctm.2013-0095","article-title":"Myogenic differentiation of muscular dystrophy-specific induced pluripotent stem cells for use in drug discovery","volume":"3","author":"Abujarour","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.celrep.2016.05.016","article-title":"Concordant but varied phenotypes among duchenne muscular dystrophy patient-specific myoblasts derived using a human iPSC-based model","volume":"15","author":"Choi","year":"2016","journal-title":"Cell Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1242\/dmm.019505","article-title":"Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with duchenne muscular dystrophy","volume":"8","author":"Lin","year":"2015","journal-title":"DMM Dis. Model. Mech."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1074248416636477","article-title":"Nicorandil, a Nitric Oxide Donor and ATP-Sensitive Potassium Channel Opener, Protects Against Dystrophin-Deficient Cardiomyopathy","volume":"21","author":"Afzal","year":"2016","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_41","first-page":"e134287","article-title":"Duchenne muscular dystrophy hiPSC-derived myoblast drug screen identifies compounds that ameliorate disease in mdx mice","volume":"5","author":"Sun","year":"2020","journal-title":"JCI Insight"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/sctm.18-0280","article-title":"Phenotypic drug screening for dysferlinopathy using patient-derived induced pluripotent stem cells","volume":"8","author":"Kokubu","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.scr.2017.10.023","article-title":"A human iPS cell myogenic differentiation system permitting high-throughput drug screening","volume":"25","author":"Uchimura","year":"2017","journal-title":"Stem Cell Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1089\/scd.2013.0135","article-title":"Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations","volume":"22","author":"Dick","year":"2013","journal-title":"Stem Cells Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.1038\/srep12831","article-title":"Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells","volume":"5","author":"Shoji","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"dmm034728","DOI":"10.1242\/dmm.034728","article-title":"Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: A tool for disease modeling and drug discovery","volume":"11","author":"Perlingeiro","year":"2018","journal-title":"Dis. Models Mech."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/mt.2009.274","article-title":"Complete genetic correction of ips cells from Duchenne muscular dystrophy","volume":"18","author":"Kazuki","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"140ra89","DOI":"10.1126\/scitranslmed.3003541","article-title":"Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy","volume":"4","author":"Tedesco","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Tanaka, A., Woltjen, K., Miyake, K., Hotta, A., Ikeya, M., Yamamoto, T., Nishino, T., Shoji, E., Sehara-Fujisawa, A., and Manabe, Y. (2013). Efficient and reproducible myogenic differentiation from human iPS cells: Prospects for modeling Miyoshi Myopathy in vitro. PLoS ONE, 8.","DOI":"10.1371\/annotation\/63972dc9-3a31-43d0-ad52-bc46fd948c03"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.stemcr.2014.10.013","article-title":"Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9","volume":"4","author":"Li","year":"2015","journal-title":"Stem Cell Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","article-title":"A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells","volume":"18","author":"Young","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1602814","DOI":"10.1126\/sciadv.1602814","article-title":"CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice","volume":"3","author":"Zhang","year":"2017","journal-title":"Sci. Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e95918","DOI":"10.1172\/jci.insight.95918","article-title":"Functional correction of dystrophin actin binding domain mutations by genome editing","volume":"2","author":"Kyrychenko","year":"2017","journal-title":"JCI Insight"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eaap9004","DOI":"10.1126\/sciadv.aap9004","article-title":"Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing","volume":"4","author":"Long","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-1-4939-8651-4_12","article-title":"Restoration of dystrophin protein expression by exon skipping utilizing CRISPR-Cas9 in myoblasts derived from DMD patient iPS cells","volume":"1828","author":"Ifuku","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","article-title":"CRISPR Correction of Duchenne Muscular Dystrophy","volume":"70","author":"Min","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1038\/s41467-019-13226-x","article-title":"CRISPR-Cas3 induces broad and unidirectional genome editing in human cells","volume":"10","author":"Morisaka","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","article-title":"Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy","volume":"26","author":"Moretti","year":"2020","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","article-title":"Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping","volume":"11","author":"Gee","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.molcel.2018.09.002","article-title":"Genetic modulation of RNA splicing with a CRISPR-guided cytidine deaminase","volume":"72","author":"Yuan","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"eabg4910","DOI":"10.1126\/sciadv.abg4910","article-title":"Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing","volume":"7","author":"Chemello","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/mt.2016.40","article-title":"Precise correction of disease mutations in induced pluripotent stem cells derived from patients with limb girdle muscular dystrophy","volume":"24","author":"Turan","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.ymthe.2019.08.011","article-title":"Gene correction of LGMD2A patient-specific iPSCs for the development of targeted autologous cell therapy","volume":"27","author":"Selvaraj","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40778-018-0145-5","article-title":"Human iPSC models to study orphan diseases: Muscular dystrophies","volume":"4","author":"Xia","year":"2018","journal-title":"Curr. Stem Cell Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.omtn.2017.10.006","article-title":"CRISPR\/Cas9-mediated deletion of CTG expansions recovers normal phenotype in myogenic cells derived from myotonic dystrophy 1 patients","volume":"9","author":"Provenzano","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2016.10.014","article-title":"CRISPR\/Cas9-induced (CTG\u22c5CAG)n repeat instability in the myotonic dystrophy type 1 locus: Implications for therapeutic genome editing","volume":"25","author":"Willemse","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"8275","DOI":"10.1093\/nar\/gky548","article-title":"Efficient CRISPR\/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells","volume":"46","author":"Dastidar","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"175628561875450","DOI":"10.1177\/1756285618754501","article-title":"Advances in spinal muscular atrophy therapeutics","volume":"11","author":"Parente","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: A nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-4939-2687-9_4","article-title":"V Annotation and Classification of CRISPR-Cas Systems","volume":"1311","author":"Makarova","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","article-title":"Clinical development on the frontier: Gene therapy for duchenne muscular dystrophy","volume":"20","author":"Asher","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/stem.1970","article-title":"Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells","volume":"33","author":"Xia","year":"2015","journal-title":"Stem Cells"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/17460441.2015.1037737","article-title":"Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery","volume":"10","author":"Corti","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nbt.2052","article-title":"Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells","volume":"29","author":"Kim","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"146561","DOI":"10.1016\/j.brainres.2019.146561","article-title":"Back to the origins: Human brain organoids to investigate neurodegeneration","volume":"1727","author":"Faravelli","year":"2020","journal-title":"Brain Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1039\/C7LC00512A","article-title":"Skeletal muscle-on-a-chip: An in vitro model to evaluate tissue formation and injury","volume":"17","author":"Agrawal","year":"2017","journal-title":"Lab Chip"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1007\/s12035-018-1305-4","article-title":"Preconditioning and cellular engineering to increase the survival of transplanted neural stem cells for motor neuron disease therapy","volume":"56","author":"Abati","year":"2018","journal-title":"Mol. Neurobiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/17\/9630\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:57:11Z","timestamp":1760165831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/17\/9630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":79,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["ijms22179630"],"URL":"https:\/\/doi.org\/10.3390\/ijms22179630","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]}}}